CpG island methylator phenotype classification improves risk assessment in pediatric T-cell acute lymphoblastic leukemia
Blood · 08.05.2025 · 145 (19) · 2161-2178
DOI: 10.1182/blood.2024026027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, erschienen am 08.05.2025. Verfasst von Fernanda Schäfer Hackenhaar und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biosciences, Umeå University, Umeå, Sweden. Hauptthemen laut MEDLINE: CpG Islands, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, DNA Methylation. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Current intensive treatment of pediatric T-cell acute lymphoblastic leukemia (T-ALL) has substantial side effects, highlighting a need for novel biomarkers to improve risk stratification. Canonical biomarkers, such as genetics and immunophenotype, are largely not used in pediatric T-ALL stratification. This study aimed to validate the prognostic relevance of DNA methylation CpG island methylator phenotype (CIMP) risk stratification in 2 pediatric T-ALL patient cohorts: the Nordic Society of Paediatric Haematology (NOPHO) ALL2008 T-ALL study cohort (n = 192) and the Dutch Childhood Oncology Group (DCOG) ALL-10/ALL-11 validation cohorts (n = 156). Both cohorts revealed that combining CIMP classification at diagnosis with measurable residual disease (MRD) at treatment day 29 (D29) or 33 (D33) significantly improved outcome prediction. The poor prognosis subgroup, characterized by CIMP low/D29 or D33 MRD ≥ 0.1%, had a cumulative incidence of relapse (pCIR5yr) of 29% and 23% and overall survival (pOS5yr) of 59.7% and 65.4%, in NOPHO and DCOG, respectively. Conversely, a good prognosis subgroup was also identified representing CIMP high/D29 or D33 MRD < 0.1% with pCIR5yr of 0% and 3.4% and pOS5yr of 98.2% and 94.8%, in NOPHO and DCOG, respectively. For NOPHO, MRD was also evaluated on D15, and the relapse prediction accuracy of CIMP/D29 MRD (0.79) and CIMP/D15 MRD (0.75) classification was comparable, indicating potential for earlier stratification. The evaluation of the biology behind the CIMP subgroups revealed associations with transcriptome profiles, genomic aberrations, and mitotic history, suggesting distinct routes for leukemia development. In conclusion, integrating MRD assessment with the novel CIMP biomarker has the potential to improve risk stratification in pediatric T-ALL and guide future therapeutic decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Biosciences, Umeå University, Umeå, Sweden.
- Department of Clinical Microbiology, Umeå University, Umeå, Sweden.
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
- Department of Clinical Immunology, University Hospital Rigshospitalet, Copenhagen, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark.
ORCID-Profile: Fernanda Schäfer Hackenhaar, Frank van Leeuwen, Hanne Vibeke Marquart, Mattias Landfors, Mats Heyman, Ulrika Norén Nyström, Sofie Degerman
Zitieren
APA
Schäfer Hackenhaar, F., Refhagen, N., Hagleitner, M., van Leeuwen, F., Marquart, H. V., Madsen, H. O., Landfors, M., Osterman, P., Schmiegelow, K., Flaegstad, T., Jónsson, Ó., Kanerva, J., Abrahamsson, J., Heyman, M., Norén Nyström, U., Hultdin, M., & Degerman, S. (2025). CpG island methylator phenotype classification improves risk assessment in pediatric T-cell acute lymphoblastic leukemia. Blood, 145(19), 2161-2178. https://doi.org/10.1182/blood.2024026027
Vancouver
Schäfer Hackenhaar F, Refhagen N, Hagleitner M, van Leeuwen F, Marquart HV, Madsen HO, et al. CpG island methylator phenotype classification improves risk assessment in pediatric T-cell acute lymphoblastic leukemia. Blood. 2025;145(19):2161-2178. doi:10.1182/blood.2024026027
BibTeX
@article{SchferHackenhaar2025,
author = {Schäfer Hackenhaar, Fernanda and Refhagen, Nina and Hagleitner, Melanie and van Leeuwen, Frank and Marquart, Hanne Vibeke and Madsen, Hans Ole and Landfors, Mattias and Osterman, Pia and Schmiegelow, Kjeld and Flaegstad, Trond and Jónsson, Ólafur and Kanerva, Jukka and Abrahamsson, Jonas and Heyman, Mats and Norén Nyström, Ulrika and Hultdin, Magnus and Degerman, Sofie},
title = {CpG island methylator phenotype classification improves risk assessment in pediatric T-cell acute lymphoblastic leukemia},
journal = {Blood},
year = {2025},
volume = {145},
number = {19},
pages = {2161--2178},
doi = {10.1182/blood.2024026027}
}
EUVIMED